**Ticker: BSE: 539561** **Status: Under Corporate Insolvency Resolution Process (CIRP)** Supha Pharmachem Limited (formerly **Remedium Lifecare Limited**) is an Indian pharmaceutical entity founded in **1988**. Historically operating as a high-volume trader of **Active Pharmaceutical Ingredients (APIs)** and specialty chemicals, the company is currently attempting a strategic pivot toward becoming a vertically integrated, research-driven healthcare provider. However, as of **March 17, 2026**, the company is under the administration of a Resolution Professional following the commencement of insolvency proceedings. --- ### Core Business Verticals & Product Portfolio The company’s operational framework is divided into two primary service pillars, supported by a diverse chemical catalog: * **Products (Trading & Distribution):** Sourcing and supplying APIs and intermediates to both innovator and generic pharmaceutical firms. * **Services (CDMO):** Transitioning into a **Contract Development and Manufacturing Organization (CDMO)**, providing cost-efficient supply chain management and manufacturing solutions. **Key Chemical & Pharmaceutical Categories:** * **Reagents & High-Value Metals:** Iodine, Selenium Metal Powder, Tellurium(IV) Oxide, Grignard Reagent, and Trimethyl Sulfoxonium Iodide (**TMSI**). * **Solvents & Industrial Chemicals:** Iso propyl Alcohol (**IPA**), Cyclohexane, Ethyl Acetate, Methylene Di Chloride, Hydrazine Hydrate, and Sodium Carbonate (**Soda Ash**). * **Finished APIs:** Atorvastatin Calcium (Amorphous/Crystalline), Montelukast Sodium, Pantoprazole Sodium, Losartan Potassium, and Ambroxol Hydrochloride. * **Specialty Materials:** Technical-grade **Lithium Carbonate** (via agreements with **Angel Partners UK** and **Alfa Chemicals Turkey**). --- ### Strategic Pivot: The "4-Point Roadmap" Prior to insolvency proceedings, management initiated a transformation strategy aimed at **4X growth** through higher-margin activities: 1. **Manufacturing Integration:** Acquisition of a **130,680 sq. ft.** facility in **Hyderabad** (Telangana) for **₹38 Crore** to establish a dedicated hub for intermediates, solvent recovery, and quality control. 2. **Global Export Expansion:** Targeting regulated markets in the **UK and Europe**. This includes a landmark **₹182.7 Crore** multi-year contract (Feb 2025–Jan 2026) for API supply to the UK. 3. **R&D Innovation:** Establishing labs focused on high-growth therapeutic areas: **CNS, Cardiovascular, Anti-infectives, Metabolic conditions, and Oncology**. 4. **Green Chemistry:** A partnership with **JiyaYu Lifesciences** to replace animal-origin raw materials with fermentation-based bioprocesses. This initiative targets an estimated **₹50 Cr** revenue potential per product at **20-25% EBITDA** margins. --- ### Financial Performance & Capital Structure The company’s financials have been characterized by extreme volatility, with a massive revenue surge in **FY24** followed by a sharp contraction in **FY25**, and a partial recovery in early **FY26**. **Comparative Financial Summary:** | Metric | H1 FY26 (Apr-Sep '25) | FY25 (Full Year) | FY24 (Full Year) | | :--- | :--- | :--- | :--- | | **Total Income** | **₹231.16 Cr** | **₹416.05 Cr** | **₹4,062.79 Cr** | | **Net Profit (PAT)** | **₹13.27 Cr** | **₹2.13 Cr** | **₹32.73 Cr** | | **EBITDA** | **₹10.44 Cr (Q2 only)** | *Declined* | *Peak* | | **Total Assets** | **₹1,623.18 Cr** | - | - | **Capital Adjustments & Fundraising:** To fund its expansion, the company aggressively modified its share capital: * **Authorized Capital:** Increased to **₹210 Crores** in **September 2025**. * **Rights Issue (May 2025):** Raised **₹47.88 Crore** at **₹1 per share**. * **Corporate Actions:** Multiple bonus issues (**3:1** in 2024; **9:5** in 2023) and stock splits (**5:1** and **2:1**) were executed to increase liquidity. * **Debt Status:** The company reports **no borrowings** from banks or financial institutions, with working capital limits below **₹5 Crore**. --- ### Critical Risk Factors & Insolvency Status Investors must note that the company is currently facing severe regulatory and legal headwinds that threaten its "going concern" status. **1. Insolvency Proceedings (CIRP):** * **NCLT Order:** Insolvency commenced on **March 17, 2026**, following a petition by **Boston Ivy Healthcare Solution**. * **Governance Collapse:** The Board of Directors is suspended. The **Interim Resolution Professional (IRP)**, **Mr. Rajesh Jhunjhunwala**, reported **non-cooperation** from suspended directors, including failure to hand over records. * **New Leadership:** The Committee of Creditors (CoC) has moved to appoint **Mr. Raju Mangilal Marshiya** as the Resolution Professional. **2. Legal & Regulatory Investigations:** | Agency/Entity | Nature of Dispute | Financial Stake | | :--- | :--- | :--- | | **GST Authorities** | Investigation into **Input Tax Credit (ITC)** (FY21-22) | **₹26.01 Crore** | | **Enforcement Agencies** | Alleged **money laundering** via shell companies | Ongoing | | **Neoloba Specialty** | Legal notice for non-payment of goods | **₹4.97 Crore** | | **Income Tax Dept** | Outstanding demand for **AY 2016-17** | **₹27.55 Lakh** | **3. Operational & Compliance Risks:** * **Credit Concentration:** A massive **₹920.6 Crore** (consolidated) is held in accounts receivable from a single **non-related party**, posing a significant liquidity risk. * **Board Non-Compliance:** Failure to maintain the mandatory **six board members** per SEBI regulations for over a year. * **Transparency Issues:** Failure to hold meetings for **Q3 FY26** results and non-compliance with **Structured Digital Database (SDD)** requirements for sensitive information. * **Moratorium:** Under **Section 14 of the IBC**, a moratorium is in place, freezing asset transfers and legal suits against the company. --- ### Global Infrastructure Despite internal turmoil, the company maintains an international footprint intended to facilitate "Green Chemistry" and global trading: * **Remlife Global PTE LTD (Singapore):** A wholly-owned subsidiary (est. **Sept 2024**) acting as the international R&D and capital markets arm. * **Sourcing Network:** Active supply chains across **India, Eastern Europe, and Southeast Asia**. * **Ethical Standards:** Claims adherence to **UCPMP 2024** for ethical marketing and **Ind AS** for accounting.